{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0002079\nAge: 76\nGender: Male\nSample ID: P-0002079-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 50.0%\n=============\nDNA Variants:\nARID1A c.4606G>C (p.D1536H) - in 16.00% of 1149 reads\nBRCA2 c.6137C>T (p.S2046L) - in 21.00% of 714 reads\nIDH2 c.817C>G (p.H273D) - in 14.00% of 872 reads\nMLL3 c.8137_8139delinsTAA (p.D2713*) - in 35.00% of 1745 reads\nMTOR c.7149G>C (p.L2383F) - in 15.00% of 944 reads\nNOTCH2 c.1076C>T (p.S359F) - in 16.00% of 1120 reads\nSPEN c.6556G>A (p.A2186T) - in 18.00% of 448 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Lung Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Alpelisib (PI3K inhibitor)\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": [\n      \"PIK3CA mutations (not present in this profile, but PI3K pathway activation suggested by MTOR mutation)\",\n      \"MTOR c.7149G>C (p.L2383F)\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209944s000lbl.pdf\"\n  }\n}"
}